Dr. Jim Woody, CEO of 180 Life Sciences Corp. ATNF, recently appeared on Benzinga’s All-Access as a guest.
180 Life Sciences is a clinical-stage biotechnology company that is dedicated to developing new drugs to address unmet needs in inflammatory diseases, fibrosis, and pain. The company’s primary focus is a unique program that uses anti-TNF to treat fibrosis and inflammation, currently in phase 2b/3 clinical trials.
As of late, 180 Life Sciences has partnered with an agreement to conduct clinical trials on a CBD formulation that can be taken in pill form. While CBD has already received FDA approval for various indications, its current oral oil administration presents challenges in terms of convenience and ease of use.
For more information, please click here.
Please note that this post contains sponsored content. It is for informational purposes only and should not be taken as investment advice.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
